QuidelOrtho Acquires LEX Diagnostics for $100M to Boost Point-of-Care Molecular Diagnostics
Event summary
- QuidelOrtho completed the acquisition of LEX Diagnostics for approximately $100 million.
- The LEX VELO System, cleared by the FDA in February 2026, delivers multiplex RT-PCR results in 6-10 minutes.
- QuidelOrtho plans to launch the LEX VELO System commercially in the U.S. later this year.
- The acquisition expands QuidelOrtho's molecular diagnostics portfolio, complementing its existing leadership in immunoassay, clinical chemistry, and transfusion medicine.
The big picture
The acquisition of LEX Diagnostics positions QuidelOrtho to capitalize on the growing demand for rapid, point-of-care molecular diagnostics. The LEX VELO System's ability to deliver lab-quality results in minutes aligns with broader industry trends toward decentralized healthcare solutions. With a $100 million investment, QuidelOrtho is reinforcing its commitment to integrating advanced diagnostics across the continuum of care, from point-of-care to hospital settings.
What we're watching
- Commercial Execution
- How QuidelOrtho will integrate and scale the LEX VELO System in the U.S. market.
- Regulatory Expansion
- The pace at which QuidelOrtho secures regulatory approvals for global expansion.
- Market Penetration
- Whether the ultra-fast PCR platform can capture significant market share in decentralized care environments.
Related topics